Stefan Suciu

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · New England Journal of Medicine · 2016 · 1.3K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

Alexander M.M. Eggermont, Vanna Chiarion‐Sileni, Jean‐Jacques Grob et al. · The Lancet Oncology · 2015 · 1.3K citations

Medicine, Oncology, Immunotherapy +15

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Alexander M.M. Eggermont, Stefan Suciu, Mario Santinami et al. · The Lancet · 2008 · 642 citations

Medicine, Oncology, Pharmacotherapy +14

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

Michael Lübbert, Stefan Suciu, Liliana Baila et al. · Journal of Clinical Oncology · 2011 · 551 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13